A study of 195 patented medicines suggests US most-favored-nation pricing could make some European launches less attractive. Because Morocco relies on foreign suppliers for innovative treatments, delays in larger markets may affect access. That does not mean every delayed European launch will be withheld from Morocco.
In February 2026, a drug for severe hypercholesterolemia was withdrawn from a European market, according to European trade reporting. Analysts linked the decision in part to changing US pricing incentives. The case shows one possible route of exposure. It does not prove that US policy alone caused the withdrawal or that every European delay will affect Morocco.
Morocco has limited influence over the launch decisions that shape access to innovative treatments. The country relies in part on medicines developed and supplied by multinational companies. Their commercial calculations are increasingly shaped by pricing policies in major markets.
In May 2025, the White House set a most-favored-nation (MFN) policy direction. It instructed federal agencies to pursue Medicare payments tied to the lowest prices in comparable countries. This was an executive policy initiative, not a law passed by Congress. Later US proposals and models extended the pricing debate beyond Medicare. One was a five-year Medicaid model that began in January 2026. By September 18, all 50 states, the District of Columbia and Puerto Rico had applied to take part. Forty states and Puerto Rico had signed agreements, according to reporting on CMS data.
Industry analysis says the US reference basket draws on a group of comparable OECD countries. Estimates put the group at 16 to 22 markets. A European launch price could therefore affect US reimbursement calculations. One study examined 195 patented medicines that accounted for $87.9 billion in annual US spending. For about three-quarters of those medicines, potential US revenue losses exceeded the combined revenue from the European benchmark countries. This is a modelled risk, not a forecast that all the products will be delayed or withdrawn.
Some manufacturers may choose to postpone entry into European markets rather than risk a larger loss across the Atlantic. Canadian industry groups have also warned that the US approach could disrupt access to existing medicines and delay new launches as companies rethink their global launch decisions. The concern reaches beyond Europe.
European reporting in September 2026 described a roughly 35% decline in new medicine launches over the ten months after the relevant US policy announcement. Industry representatives also warned that companies might be more cautious about launching in Germany. Separately, nine major pharmaceutical groups argued that Europe was losing ground in the competition for investment and innovation. These figures and warnings describe pressure on launch activity and industry expectations. They do not show that MFN policy was the sole cause of the decline.
Many of these decisions happen before medicines reach Morocco. A representative of the Moroccan pharmaceutical industry, speaking anonymously, said North American or European companies mainly develop next-generation treatments in oncology, immunology, rare diseases and complex neurological conditions. Manufacturers commonly give priority to the United States and major European markets. Other countries may come later.
Commercial priorities, registration dossier preparation and health systems' ability to pay all shape that sequence. Morocco's smaller market and low household medicine consumption can put it further down the launch queue, according to the industry representative. A delay in Paris or Berlin may therefore affect when a treatment reaches Rabat. It does not mean the medicine will never be registered or supplied in Morocco.
Access also depends on the support patients receive after a treatment becomes available. A separate account of oncology nursing in Algeria examined another challenge in cancer care.
Moroccan pharmacies already face recurring shortages of essential medicines. These include insulin, some antihypertensives, thyroid drugs, certain psychotropic medicines and ADHD treatments. Such shortages are different from delays in launching innovative drugs. But they add pressure to a system where patients may already struggle to get treatment. The problems need different responses. Launch delays concern commercial and regulatory timing. Shortages can also involve procurement, distribution and continuity of supply.
On June 1, 2026, Health and Social Protection Minister Amine Tehraoui outlined a plan to address shortages in the House of Representatives. A month later, Representative Naïma El Fathaoui submitted a written question about continuing problems with chronic-disease treatments. These parliamentary and ministerial interventions document concern about medicine availability. They do not, by themselves, assess the likely effects of MFN policy.
The European Union's revised pharmaceutical rules require companies to make a new medicine available in a member state within three years of its marketing authorisation. Otherwise, they risk losing two years of regulatory protection. The safeguard may give European authorities leverage. It does not force a company to launch in every country or settle the possible effect of US reference pricing. The account reviewed here identifies no equivalent launch requirement in Morocco.
Morocco's Ministry of Health and Social Protection and the Moroccan Agency for Medicines and Health Products have not publicly documented an assessment of MFN-related risks to access to innovative treatments in the account reviewed here. In mid-June 2026, European health ministers asked the European Commission to assess the policy's impact. No equivalent review in Rabat is identified. An assessment published through the Health Ministry portal could help separate plausible supply-chain risks from demonstrated effects. It could also clarify which actions are within national reach.
For a country that relies on medicines developed abroad, the practical task is to track registration timelines, import dependence and shortages separately. Morocco can also monitor launch decisions in major supplier markets. Public communication from the Ministry and reporting by Morocco's official news agency MAP could make supply risks and policy responses easier to scrutinize. The evidence points to a vulnerability, not a certainty. European launch decisions may affect Morocco, but local monitoring and transparent data are needed to assess the scale and timing.
